Clinical Trials

17 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell, Somatostatinoma, Carcinoma, Adenosquamous

NCT05687123 2026-05-13

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

24 enrolled

Adenoma, Islet Cell, Pancreatic Neoplasms

NCT04924075 2026-05-11

MK-6482-015

322 enrolled 1 FDA

CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT07554560 2026-05-07

Nutrition Intervention for Pancreatic Cancer

18 enrolled

Phase 3 Active not recruiting

Adenoma, Islet Cell, Exocrine Pancreatic Insufficiency

NCT03375320 2026-05-01

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

298 enrolled 14 charts 1 FDA

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT06943755 2026-04-17

STELLAR-311

Phase 2/3 Recruiting

440 enrolled

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT07165132 2026-04-13

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

104 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT06141369 2026-04-09

Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)

21 enrolled

Adenoma, Islet Cell, Adrenocortical Carcinoma, Carcinoma, Medullary

NCT05477576 2026-03-30

ACTION-1

Phase 3 Recruiting

338 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

18 enrolled

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

133 enrolled

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT06202066 2026-03-11

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

60 enrolled

Adenoma, Islet Cell

NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

NCT01824875 2026-02-25

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

144 enrolled 15 charts

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT03879694 2026-02-06

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

19 enrolled

Adenoma, Islet Cell

NCT07273409 2026-01-22

PANTODON

200 enrolled

Adenoma, Islet Cell

NCT04505553 2026-01-21

Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer

78 enrolled 14 charts

Gastro-enteropancreatic neuroendocrine tumor, Anus Neoplasms, Appendiceal Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Adenoma, Islet Cell, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT07328607 2026-01-21

Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy

90 enrolled

Adenoma, Islet Cell

NCT03891784 2026-01-14

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell

NCT06663072 2026-01-09

Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

25 enrolled

Adenoma, Islet Cell

NCT03600233 2025-12-23

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

34 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell, Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05040360 2025-12-15

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Phase EARLY_PHASE1 Active not recruiting

141 enrolled

Adenoma, Islet Cell

NCT06148636 2025-11-04

A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

24 enrolled

Adenoma, Islet Cell, Recurrence, Neuroendocrine Tumors

NCT02159989 2025-10-20

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

GastrointestinalGynecologic

83 enrolled 21 charts

Fibrolamellar hepatocellular carcinoma, Adenoma, Islet Cell, Neoplasm Metastasis, Ovarian Neoplasms

NCT07121478 2025-10-01

Patients With High-grade Pancreatic Neuroendocrine Tumors

Phase 2 Enrolling by invitation

46 enrolled

Adenoma, Islet Cell, Neuroendocrine Tumors

NCT04520932 2025-05-25

RFANET

82 enrolled

Adenoma, Islet Cell

NCT05247905 2025-04-02

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

31 enrolled

Adenoma, Islet Cell

NCT05037461 2024-12-18

PRIME

Adenoma, Islet Cell, Multiple Endocrine Neoplasia Type 1

NCT05568017 2024-11-20

NeoNet

Phase 2 Terminated

11 enrolled

Adenoma, Islet Cell

NCT06024343 2024-11-07

Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Exposure, Repair or Reconstruction

Phase NA Completed

230 enrolled

Adenoma, Islet Cell, Pancreatic Neoplasms

NCT05610826 2024-10-26

Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver

Phase 1/2 Withdrawn

Adenoma, Islet Cell, Pancreatic Neoplasms

NCT05997056 2024-07-16

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

21 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT06472388 2024-06-25

EVENET

100 enrolled

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors, Disease Progression

NCT01466036 2024-03-05

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

61 enrolled 9 charts

Phase NA Not yet recruiting

Carcinoid Tumor, Adenoma, Islet Cell, Neoplasm Metastasis

NCT06167421 2023-12-12

Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreatectomy

240 enrolled

Phase 2 Not yet recruiting

Adenoma, Islet Cell, Pancreatic Neoplasms

NCT06158516 2023-12-06

A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

100 enrolled

Adenoma, Islet Cell

NCT02231723 2023-11-18

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

139 enrolled

Pancreatic cancer, adult, Digestive System Neoplasms, Endocrine Gland Neoplasms, Adenoma, Islet Cell, Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Islet Cell, Carcinoma, Pancreatic Ductal

NCT00427349 2023-07-05

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

46 enrolled 7 charts

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

Phase 2/3 Terminated

36 enrolled 14 charts

EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT05800106 2023-04-10

A Bioequivalence Study of Sunitinib Malate Capsules.

GastrointestinalGenitourinarySarcoma

24 enrolled

Carcinoma, Renal Cell, Adenoma, Islet Cell, Gastrointestinal Stromal Tumors

NCT05566093 2022-10-04

EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors

Phase NA Unknown

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell

NCT05554744 2022-09-27

EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors

Phase NA Unknown

Phase 2 Not yet recruiting

Adenoma, Islet Cell, Multiple Endocrine Neoplasia Type 1

NCT05316480 2022-04-07

Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms

42 enrolled

Adenoma, Islet Cell

NCT03147768 2022-04-06

LTW

EndocrineGastrointestinal

11 enrolled

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Pancreatic Cyst, Pancreatic Neoplasms, Pancreatic Pseudocyst

NCT02294006 2021-09-09

MetNET1

Phase 2 Unknown

26 enrolled

Adenoma, Islet Cell

NCT02355535 2020-09-24

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1

48 enrolled

Adenoma, Islet Cell, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT02575300 2020-09-11

Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

20 enrolled 11 charts